Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

Appeal  

Solving Kids' Cancer : Appeal letter ^{PDF 463 KB} 30 September 2016  

Solving Kids' Cancer : Scrutiny letter ^{PDF 165 KB} 30 September 2016  

Solving Kids' Cancer : Response to scrutiny letter ^{PDF 449 KB} 30 September 2016  

Solving Kids' Cancer : Final scrutiny letter ^{PDF 153 KB} 30 September 2016  

Solving Kids' Cancer : Written submission ^{PDF 964 KB} 03 October 2016  

Solving Kids' Cancer : Written submission ^{PDF 236 KB} 03 October 2016  

Solving Kids' Cancer : Written submission ^{PDF 210 KB} 03 October 2016  

Appeal decision ^{PDF 306 KB} 29 November 2016  

Final appraisal determination: 2  

Final appraisal determination document ^{PDF 398 KB} 15 July 2016  

Committee papers ^{PDF 2.96 MB} 15 July 2016  

Draft guidance  

Committee papers ^{PDF 7.59 MB} 05 November 2015  

Appraisal consultation document ^{PDF 412 KB} 05 November 2015  

Final matrix ^{PDF 128 KB} 27 October 2015  

Final scope ^{PDF 35 KB} 13 February 2017  

Final matrix ^{PDF 99 KB} 13 February 2017  

Draft scope and provisional matrix comments table (post-referral) ^{PDF 168 KB} 13 February 2017  

Equality impact assessment (Scoping) ^{PDF 174 KB} 13 February 2017  

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]: draft scope for consultation (pre-referral) - November 2014  

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]: draft scope for consultation (pre-referral) - November 2014 ^{PDF 105 KB} 05 May 2015  

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]: provisional matrix (pre-referral) - November 2014  

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]: provisional matrix (pre-referral) - November 2014 ^{PDF 99 KB} 05 May 2015